Perspectives on the Management of Plaque Psoriasis

A panel of experts review the nature of plaque psoriasis and the mechanism of action of several classes of targeted therapy.

Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.

The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.